BRAF and non-small cell lung carcinoma: A phase 2, multicenter, nonrandomized, open-label study of untreated and previously treated stage IV, metastatic NSCLC patients harboring BRAF V600E mutations were treated with dabrafenib to determine its therapeutic activity [49].